Feb 12 (Reuters) - Australian biotech company CSL Ltd CSL.AX on Wednesday posted an 8% rise in first-half profit and raised its earnings forecast for the full year, helped by strong demand for its immunoglobulin (IG) products.
The company, which makes treatments for blood-related diseases and vaccines for influenza, posted a net profit of $1.25 billion for the six months ended Dec. 31, compared with $1.16 billion a year earlier.
CSL raised its after-tax net profit forecast for the full year to a range of $2.11 billion to $2.17 billion at constant currency.